Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy

References

• Couchoud C, Fagnoni P, Aubin F, et al. Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. Cancer Immunol Immunother. 2020;69(10):1339–1958.
   Web of Science ®Google Scholar
• Gauci ML, Lanoy E, Champiat S, et al. Long-Term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin Cancer Res. 2019;25(3):946–956.
   PubMed Web of Science ®Google Scholar
• Maly J, Alinari L. Pembrolizumab in classical Hodgkin's lymphoma. Eur J Haematol. 2016;97(3):219–227.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• Dietz A, Welslau M, Hahn D, et al. HANNA: real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany. J Clin Oncol. 2020;38(15_suppl):6532–6532.
   Web of Science ®Google Scholar
• Minami S, Ihara S, Ikuta S, et al. Gustave Roussy immune score and Royal Marsden hospital prognostic score are biomarkers of immune-checkpoint inhibitor for non-small cell lung cancer. World J Oncol. 2019;10(2):90–100.
   PubMedGoogle Scholar
• Minami S, Ihara S, Komuta K. Gustave Roussy immune score is a prognostic factor for chemotherapy-naive pulmonary adenocarcinoma with wild-type epidermal growth factor receptor. World J Oncol. 2019;10(1):55–61.
   PubMedGoogle Scholar
• Bigot F, Castanon E, Baldini C, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy immune score (GRIm-Score). Eur J Cancer. 2017;84:212–218.
   PubMed Web of Science ®Google Scholar
• Takamori S, Takada K, Shimokawa M, et al. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 2021;152:27–33.
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Komuta K. Gustave Roussy immune score and Royal Marsden hospital prognostic score are prognostic markers for extensive disease of small cell lung cancer. World J Oncol. 2020;11(3):98–105.
   PubMedGoogle Scholar
• Lenci E, Cantini L, Pecci F, et al. The Gustave Roussy immune (GRIm)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab. J Clin Med. 2021;10(5):1005.
   PubMed Web of Science ®Google Scholar
• Simera I, Moher D, Hoey J, et al. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40(1):35–53.
   PubMed Web of Science ®Google Scholar
• Gleiss A, Zeillinger R, Braicu EI, et al. Statistical controversies in clinical research: the importance of importance. Ann Oncol. 2016;27(7):1185–1189.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced Renal-Cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–167.
   PubMed Web of Science ®Google Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study . J Clin Oncol. 2019;37(28):2518–2527.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026.
   PubMed Web of Science ®Google Scholar
• Guirgis HM. The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. J Immunother Cancer. 2018;6(1):15.
   PubMed Web of Science ®Google Scholar
• Nesline MK, Knight T, Colman S, et al. Economic burden of checkpoint inhibitor immunotherapy for the treatment of non-small cell lung cancer in US clinical practice. Clin Ther. 2020;42(9):1682–1698.e7.
   PubMed Web of Science ®Google Scholar
• Abi Jaoude J, Kouzy R, Mainwaring W, et al. Performance status restriction in phase III cancer clinical trials. J Natl Compr Canc Netw. 2020;18(10):1322–1326.
   PubMed Web of Science ®Google Scholar
• Khaki AR, Li A, Diamantopoulos LN, et al. Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020;126(6):1208–1216.
   PubMed Web of Science ®Google Scholar
• Simcock R, Wright J. Beyond performance status. Clin Oncol (R Coll Radiol). 2020;32(9):553–561.
   PubMed Web of Science ®Google Scholar
• Chow R, Bruera E, Temel JS, et al. Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and Meta-analysis. Support Care Cancer. 2020;28(5):2071–2078.
   PubMed Web of Science ®Google Scholar
• Chow R, Zimmermann C, Bruera E, et al. Inter-rater reliability in performance status assessment between clinicians and patients: a systematic review and Meta-analysis. BMJ Support Palliat Care. 2020;10(2):129–135.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Hui D, Zhang Y, et al. Differences in performance status assessment among palliative care specialists, nurses, and medical oncologists. J Pain Symptom Manage. 2015;49(6):1050–1058 e1052.
   PubMed Web of Science ®Google Scholar
• Fang S, Sui D, Wang Y, et al. Association of vitamin D levels with outcome in patients with melanoma after adjustment for C-Reactive protein. J Clin Oncol. 2016;34(15):1741–1747.
   PubMed Web of Science ®Google Scholar
• Fang S, Wang Y, Sui D, et al. C-reactive protein as a marker of melanoma progression. J Clin Oncol. 2015;33(12):1389–1396.
   PubMed Web of Science ®Google Scholar
• Iivanainen S, Ahvonen J, Knuuttila A, et al. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. ESMO Open. 2019;4(4):e000531.
   PubMed Web of Science ®Google Scholar
• Nosrati A, Tsai KK, Goldinger SM, et al. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017;116(9):1141–1147.
   PubMed Web of Science ®Google Scholar
• Diem S, Kasenda B, Spain L, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. 2016;114(3):256–261.
   PubMed Web of Science ®Google Scholar
• Gao D, Ma X. Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma. Panminerva Med. 2017;59(4):332–337.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and Meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961–970.
   PubMed Web of Science ®Google Scholar
• Oya Y, Yoshida T, Kuroda H, et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget. 2017;8(61):103117–103128.
   PubMedGoogle Scholar
• Taniguchi Y, Tamiya A, Isa SI, et al. Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. Anticancer Res. 2017;37(10):5857–5862.
   PubMed Web of Science ®Google Scholar
• Ichihara E, Harada D, Inoue K, et al. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer. 2020;139:140–145.
   PubMed Web of Science ®Google Scholar
• Zhang S, Pease DF, Kulkarni AA, et al. Real-World outcomes and clinical predictors of immune checkpoint inhibitor monotherapy in advanced lung cancer. Clin Med Insights Oncol. 2021;15:11795549211004489.
   Web of Science ®Google Scholar
• Herrmann T, Mione C, Montoriol PF, et al. Body mass index, sarcopenia, and their variations in predicting outcomes for patients treated with nivolumab for metastatic renal cell carcinoma. Oncology. 2022;100(2):114–123.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Ricciuti B, Tiseo M, et al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression >/= 50%: a multicenter study with external validation. J Immunother Cancer. 2020;8(2):e001403.
   PubMed Web of Science ®Google Scholar
• Kasahara N, Sunaga N, Tsukagoshi Y, et al. Post-treatment Glasgow prognostic score predicts efficacy in advanced non-small-cell lung cancer treated with anti-PD1. Anticancer Res. 2019;39(3):1455–1461.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Z, Hu Y, et al. Pretreatment neutrophil-to-Lymphocyte ratio (NLR) may predict the outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). Front Oncol. 2020;10:654.
   PubMed Web of Science ®Google Scholar